Sage Therapeutics

SAGE Therapeutics is a central nervous system (CNS) product focused company building a portfolio of new therapies to meet the growing unmet medical needs resulting from a range of CNS disorders, including schizophrenia, depression, pain and traumatic brain injury. SAGE Therapeutics’ proprietary Positive and Negative Allosteric Modulator (PANAM) chemistry platform targets the primary excitatory and inhibitory neurotransmitter systems in the brain and enables the development of allosteric modulators that fine tune and balance neuronal activity that is disrupted in CNS disorders. Specifically, SAGE Therapeutics is focused on non-benzodiazepine and non-glycine approaches to modulating GABA and glutamate receptors, respectively.


Date Type Amount Investors Valuation
10/01/11 Series A 35M Third Rock Ventures Unknown


Steven Paul (Founder, CSO)

Kiran Reddy (Head of Business Development and Operations)

Kevin Starr (CEO)

View more details about the people at Sage Therapeutics